Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa.

ABSTRACT:

Background

Activated coagulation factor XI (FXIa) contributes to the development and propagation of thrombosis but plays only a minor role in hemostasis; therefore, it is an attractive antithrombotic target.

Objectives

To evaluate the pharmacology of asundexian (BAY 2433334), a small molecule inhibitor targeting FXIa, in vitro and in various rabbit models.

Methods

The effects of asundexian on FXIa activity, selectivity versus other proteases, plasma thrombin generation, and clotting assays were evaluated. Antithrombotic effects were determined in FeCl₂ - and arterio-venous (AV) shunt models. Asundexian was administered intravenously or orally, before or during thrombus formation, and with or without antiplatelet drugs (aspirin and ticagrelor). Potential eff

SUBMITTER: Heitmeier S 

PROVIDER: S-EPMC9313898 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature